接受急性肾替代治疗的ICU幸存者出院后主要不良心血管事件
韩国全国性人群队列研究基于医保数据库,纳入12,380例接受急性肾替代治疗的ICU幸存者与382,018例对照。急性肾替代治疗组出院后主要不良心血管事件(校正HR 1.463 [1.323-1.619])、全因死亡(校正HR 1.323 [1.256-1.393])和终末期肾病(校正HR 18.110 [15.779-20.786])风险均高于对照组。连续肾替代治疗组(6,891例)与仅间歇肾替代治疗组(5,034例)的主要不良心血管事件风险相当(校正HR 1.049 [0.888-1.239],p=0.575)。作者认为临床医生应关注此类患者出院后长期主要不良心血管事件风险升高,并考虑适当的危险因素管理。
要点
- 接受急性肾替代治疗的ICU幸存者出院后主要不良心血管事件风险高于未接受者(校正HR 1.463 [1.323-1.619],p<0.001)。
- 该组全因死亡风险升高(校正HR 1.323 [1.256-1.393],p<0.001),进展至终末期肾病风险显著升高(校正HR 18.110 [15.779-20.786],p<0.001)。
- 连续肾替代治疗与仅间歇肾替代治疗相比,出院后主要不良心血管事件风险相当(校正HR 1.049 [0.888-1.239],p=0.575)。
- 作者认为临床医生应关注急性肾替代治疗患者长期主要不良心血管事件风险升高,并考虑适当的危险因素管理。
适用人群与场景
- 韩国政府指定三级医院的ICU幸存者,年龄≥20岁,ICU治疗≥24小时,出院后存活超过30天,且无既往ICU入住史、无主要不良心血管事件史及主要不良心血管事件相关心脑血管疾病史。
- 研究组为接受急性肾替代治疗的ICU幸存者,对照组为未接受急性肾替代治疗者;连续肾替代治疗组与仅间歇肾替代治疗组进行比较。
研究设计与关键结果
- 研究类型:基于韩国医保理赔数据库的全国性人群研究;纳入急性肾替代治疗患者12,380例,对照组382,018例;研究组中连续肾替代治疗6,891例,仅间歇肾替代治疗5,034例。
- 主要终点主要不良心血管事件(包括急性心肌梗死、血运重建和急性缺血性卒中):急性肾替代治疗组风险高于对照组,校正HR 1.463(95%CI 1.323-1.619),p<0.001。
- 全因死亡:急性肾替代治疗组高于对照组,校正HR 1.323(95%CI 1.256-1.393),p<0.001。
- 终末期肾病:急性肾替代治疗组高于对照组,校正HR 18.110(95%CI 15.779-20.786),p<0.001。
- 连续肾替代治疗组与仅间歇肾替代治疗组比较,主要不良心血管事件风险相当,校正HR 1.049(95%CI 0.888-1.239),p=0.575。
证据类型、等级与局限
- 证据类型:基于全国医保理赔数据库的人群研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为临床医生应关注接受急性肾替代治疗的ICU幸存者出院后长期主要不良心血管事件风险升高,并考虑适当的危险因素管理。
- 连续肾替代治疗与仅间歇肾替代治疗之间未发现出院后主要不良心血管事件风险的显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Long-term risk of a major adverse cardiovascular events in ICU survivors who underwent acute renal replacement therapy requires further investigation.
DESIGN: Nationwide population-based study using the claims database of Korea.
SETTING: Index admission cases of ICU survivors in government-designated tertiary hospitals PATIENTS:: The study group consisted of ICU survivors who underwent acute renal replacement therapy, and the control group consisted of those without acute renal replacement therapy. Patients were excluded if they 1) were under age 20, 2) expired within 30 days after discharge, 3) received ICU care for less than 24 hours, 4) had a previous ICU admission, 5) had a history of major adverse cardiovascular event, or 6) had a major adverse cardiovascular event-related cardio/cerebrovascular diseases. The outcomes of the patients who received continuous renal replacement therapy were compared with those of patients who received only intermittent renal replacement therapy.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Information regarding patient characteristics and treatment modalities was collected and adjusted. The main outcome was major adverse cardiovascular event, including acute myocardial infarction, revascularization, and acute ischemic stroke. Patient mortality and progression to end-stage renal disease were also evaluated. We included 12,380 acute renal replacement therapy patients and 382,018 patients in the control group. Among the study group, 6,891 patients were included in the continuous renal replacement therapy group, and 5,034 in the intermittent renal replacement therapy group. The risks of major adverse cardiovascular event (adjusted hazard ratio, 1.463 [1.323-1.619]; p < 0.001), all-cause mortality (adjusted hazard ratio, 1.323 [1.256-1.393]; p < 0.001), and end-stage renal disease (adjusted hazard ratio, 18.110 [15.779-20.786]; p < 0.001) were higher in the acute renal replacement therapy patients than the control group. When we compared the continuous renal replacement therapy patients with the intermittent renal replacement therapy patients, the risk of major adverse cardiovascular event was comparable (adjusted hazard ratio, 1.049 [0.888-1.239]; p = 0.575).
CONCLUSIONS: Clinicians should note the increased risk of a long-term major adverse cardiovascular event in acute renal replacement therapy patients and consider appropriate risk factor management. Significant difference in the risk of postdischarge major adverse cardiovascular event was not identified between continuous renal replacement therapy and intermittent renal replacement therapy.
参考来源
- Park S, Lee S, Kang MW, et al. Postdischarge Major Adverse Cardiovascular Events of ICU Survivors Who Received Acute Renal Replacement Therapy. Crit Care Med. 2018. PMID: 30095497. doi:10.1097/CCM.0000000000003357
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。